Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer

Cancer Genomics - Proteomics

GIORDANO B. CHIARA³  STEFANO M.M. BASSO³  FRANCO LUMACHI²  LUISA FOLTRAN¹ 

[1] edical Oncology, S. Maria degli Angeli Hospital, Pordenone, Italyedical Oncology, S. Maria degli Angeli Hospital, Pordenone, Italyedical Oncology, S. Maria degli Angeli Hospital, Pordenone, Italy;niversity of Padua, School of Medicine, Department of Surgery, Oncology and Gastroenterology (DiSCOG), Padova, Italyniversity of Padua, School of Medicine, Department of Surgery, Oncology and Gastroenterology (DiSCOG), Padova, Italyniversity of Padua, School of Medicine, Department of Surgery, Oncology and Gastroenterology (DiSCOG), Padova, Italy;urgery 1, S. Maria degli Angeli Hospital, Pordenone, Italyurgery 1, S. Maria degli Angeli Hospital, Pordenone, Italyurgery 1, S. Maria degli Angeli Hospital, Pordenone, Italy

关键词: Proteomics;    genomics;    breast cancer;    early breast cancer;    targeted therapies;    HER2;    triple-negative;    VEGF;    trastuzumab;    mTOR;    review;   

DOI  :  

来源: Delinasios GJ CO

【 摘 要 】

Proteomics allows for better understanding of the function and regulation of cancer cells mediated by intra- and extracellular signaling networks. Integrating such information with clinicopathological characteristics of the tumor may lead to either detection of disease biomarkers useful to differentiate high-from low-risk patients, or to identification of new drug targets. Adjuvant chemotherapy is currently a personalized treatment strategy, especially for breast cancer (BC) patients, and the risk assessment of each patient influences its use because the benefit strictly correlates with the level of risk. Luminal A BCs are endocrine therapy (ET)-sensitive but exhibit low sensitivity to chemotherapy, while luminal B cancers, according to the Ki-67 proliferation rate may require for chemotherapy in addition to ET, and HER2-positive tumors derive benefit from adjuvant chemotherapy containing an anthracycline, a taxane and trastuzumab for one year. Triple-negative BCs have a high degree of genomic instability exhibiting a more aggressive clinical course with respect to other types of BC, and the anthracycline-taxane regimen constitutes the standard approach. Studies considering the use of targeted approaches (drugs), including poly (ADP-ribose) polymerase (PARP-1), vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR) inhibitors, or EFGR and HER2 blockers, are still under evaluation. In the genomic era, promising new targeted-therapies are worthy of further investigation, and mTOR inhibitors have been used for patients with high-risk ER-positive and HER2-negative tumors. In the near future, genetic and molecular profiling of BC will help to better-categorize patients, determine the choice of chemotherapy in low-risk, or intensify the treatment in high-risk cancer patients, eventually revealing new targeted agents.

【 授权许可】

Unknown